New Delhi, India, August 22, 2015 --(PR.com
)-- DelveInsight, the leading market research and consulting company has received immense positive feedback on its report PD-1 and PD-L1 inhibitors and Chimeric Antigen Receptor (CAR)-T cell Immunotherapy - Competitive Landscape, Pipeline and Market Analysis, 2015.. In addition to this their research expertise provides their clients with up to date information of market till the date of order.
DelveInsight Report, “PD-1 and PD-L1 inhibitors and Chimeric Antigen Receptor (CAR)-T cell Immunotherapy - Competitive Landscape, Pipeline and Market Analysis, 2015” gives the comprehensive insights on the PD-1 and PD-L1 Inhibitors and CART Immunotherapy. The report provides the analysis on the worldwide therapeutic market which gives information of Marketed molecules, detailed profiling of Pipeline assets and their pathways. The report covers the therapeutics assessment of pipeline molecules by mechanism of action (MoA), route of administration (RoA), molecule type, along with latest updates. Report also covers other Commercial Aspects such as the Current and Future Market, Barriers and challenges, SWOT analysis information on ongoing collaborations for the development of combinations regimens.
There are 38 drugs are in pipeline with approximate 245 active clinical studies for PD-1/PDL-1 inhibitors. Companies have also gone in collaboration with different partners like Bristol, Merck, Astrazeneca and Roche for evaluating their drugs in combination with Immune Checkpoint Inhibitors (PD-1/PD-L1). There are total 28 companies found which have partnered with these Big Pharmas for 37 drugs or immunotherapies.
The Chimeric Antigen Receptor (CAR)-T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2015 Report gives insights on 35 products targeting 20 different antigens and 9 different technologies. It also includes around 35+ companies which are active in this field.
Key Topics Covered:
· Collaborations and Deals
· Licensing Opportunities
· Pipeline Scenario and product profiles
· CAR-T Technologies and Targeted Antigens
· Adverse effects of CAR-T
· Market Drivers and Barriers
DelveInsight is offering the Report on PD-1/PDL-1 inhibitors at a price of USD 2,950 as a single user license, USD 5,800 as a site license and USD 8,850 as a Global/Enterprise License.
DelveInsight is offering the Report on Chimeric Antigen Receptor (CAR)-T cell Immunotherapy at a price of USD 1,750 as a single user license, USD 3,500 as a site license and USD 5,000 as a Global/Enterprise License.
These Reports will help to identify emerging players with potentially strong product information, licensing opportunities and helps you to create effective counter-strategies to gain competitive advantage.
For more information on Pipeline Insight Reports, email at info@delveInsight.com
DelveInsight is a leading Business Consulting and Market Research Firm. We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this, DelveInsight also deals in providing custom research services in coherence with interest area of the clients.